INVITATION
Novartis – Unmet needs in oncogene-driven NSCLC: how do we close the gap?
INVITATION
Daiichi Sankyo – Advances in Antibody Drug Conjugates in Solid Tumors: Current Treatments and Emerging Therapies
INVITATION
AstraZeneca – Emerging immuno-oncology options in metastatic NSCLC and SCLC: Clinical evidence and future perspectives
